Éclat Pharmaceuticals, L. L. C.

Louis, Missouri. With a focus on the development, approval, and commercialization of niche brands and generic products, Éclat aims to improve medicine and enhance patient outcomes. True to its name, Éclat, which is of French origin and signifies success, thrives on finding creative and cost-effective ways to deliver pharmaceutical therapy to patients.

Éclat has taken on several promising product opportunities and is actively involved in their development. With expertise in the regulatory process, development, manufacturing, and distribution, the company is well-positioned to bring these products to market. Moreover, Éclat intends to leverage its own sales and marketing proficiency to successfully introduce these products to consumers.

Flamel Technologies SA acquired Éclat Pharmaceuticals in March 2012, resulting in a more vertically integrated company. This acquisition has enabled Éclat to enhance its development and commercial expertise, expand its drug delivery platforms, and create more value in the near and mid-term. To learn more about Éclat Pharmaceuticals and explore their offerings, please visit the Flamel Technologies SA website